Ali Nehme
Ali Nehme has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Kazem Zibara
Research and Analysis Platform in Environmental Sciences (EDST-PRASE), Lebanese University, Hadath P.O. Box 14-6573, Lebanon
9 shared publications - Firas Kobeissy
Center for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology and Neuroscience Institute, Morehouse School of Medicine (MSM), Atlanta, Georgia
4 shared publications Catherine Cerutti
From the EA4173, Functional Genomics of Arterial Hypertension, UCBL-1, Lyon, France (A.N., C.C.); and ER045, Laboratory of Stem Cells, DSST (A.N., K.Z.) and Department of Biology, Faculty of Sciences-I (K.Z.), Lebanese University, Beirut, Lebanon
3 shared publications- Giampiero Bricca
Université Lyon1, INSERM, ERI22
3 shared publications - Fouad A. Zouein
Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
2 shared publications - Frédéric Mazurier
Univ Rennes, CNRS, INSERM, IGDR (Institute Genetics and Development of Rennes) - UMR 6290, ERL U1305, France
2 shared publications
Latest Publications
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Targeting Tissue-Specific Enzymatic Cascades of Local Angiotensin System in Human Atheroma
Ciblage Tissu-Spécifique des Cascades Enzymatiques de l’Angiotensinogène dans l’Athérome Humain: L'Athérosclérose est la principale cause de décès et d'invalidité dans le monde. L'implication du système rénine-angiotensine-aldostérone (RAAS) dans le développement de la maladie est expérimentalement et cliniquement bien documentée. Toutefois, en raison de la complexité du système, ces études ne donnent pas de vision claire sur l'association entre le système et la maladie. À cet égard, nous avons étudié l'organisation fonctionnelle d'un ensemble de 37 gènes codant pour les composants classiques et nouvellement découverts du RAAS, y compris les substrats, les enzymes et les récepteurs. Cet ensemble a été appelé RAAS étendu (extRAAS). En utilisant une analyse statistique des données du transcriptome de l'athérome carotidien humain, nous avons révélé des caractéristiques spéciales de l'expression de l'extRAAS associées au remodelage athéromateux. Une caractéristique importante de ce modèle est la coordination de 2 groupes de gènes qui sont connus pour favoriser la formation de l'athérome. Le premier groupe est constitué de gènes codant pour les peptidases de l'angiotensine, y compris ACE, CTSG, CTSD et RNPEP. Le deuxième groupe est constitué des gènes codant pour les récepteurs AGTR1, MR, GR et LNPEP
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Targeting Tissue-Specific Enzymatic Cascades of Local Angiotensin System in Human Atheroma
Ciblage Tissu-Spécifique des Cascades Enzymatiques de l’Angiotensinogène dans l’Athérome Humain: L'Athérosclérose est la principale cause de décès et d'invalidité dans le monde. L'implication du système rénine-angiotensine-aldostérone (RAAS) dans le développement de la maladie est expérimentalement et cliniquement bien documentée. Toutefois, en raison de la complexité du système, ces études ne donnent pas de vision claire sur l'association entre le système et la maladie. À cet égard, nous avons étudié l'organisation fonctionnelle d'un ensemble de 37 gènes codant pour les composants classiques et nouvellement découverts du RAAS, y compris les substrats, les enzymes et les récepteurs. Cet ensemble a été appelé RAAS étendu (extRAAS). En utilisant une analyse statistique des données du transcriptome de l'athérome carotidien humain, nous avons révélé des caractéristiques spéciales de l'expression de l'extRAAS associées au remodelage athéromateux. Une caractéristique importante de ce modèle est la coordination de 2 groupes de gènes qui sont connus pour favoriser la formation de l'athérome. Le premier groupe est constitué de gènes codant pour les peptidases de l'angiotensine, y compris ACE, CTSG, CTSD et RNPEP. Le deuxième groupe est constitué des gènes codant pour les récepteurs AGTR1, MR, GR et LNPEP
- Open Access
- 26 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (10)
Distinct immune landscapes characterize highly versus minimally invasive brain metastases
Brain metastases (BrMs) occur in approximately 30% of cancer patients, causing nearly one-fifth of cancer deaths. While immune checkpoint inhibitors (ICIs) benefit some BrM patients, responses remain highly variable. This variability partly reflects distinct histopathological growth patterns that include minimally invasive (MI) and highly invasive (HI) brain BrMs. Here we show that MI BrMs exhibit robust immune infiltration, whereas HI lesions are immunosuppressed. However, histological differentiation between MI and HI can be challenging because of subjective margin assessment. Here, using highly multiplexed spatial proteomics on 119 tumor sections from 46 patients with BrMs, we identify CHI3L1 as a key mediator of the immunosuppressive microenvironment in HI BrMs. In preclinical models, genetic deletion of CHI3L1 converts immune-cold metastases into lymphocyte-rich, ICI-responsive lesions infiltrated by granzyme B + CD8 + T cells. In BrM patients treated with ICI, immunohistochemical quantification of CHI3L1 expression was a stronger predictor of ICI response than traditional MI/HI classification. Thus, CHI3L1 represents a promising biomarker and therapeutic target for BrMs.
- 26 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (10)
Open AccessDistinct immune landscapes characterize highly versus minimally invasive brain metastases
Brain metastases (BrMs) occur in approximately 30% of cancer patients, causing nearly one-fifth of cancer deaths. While immune checkpoint inhibitors (ICIs) benefit some BrM patients, responses remain highly variable. This variability partly reflects distinct histopathological growth patterns that include minimally invasive (MI) and highly invasive (HI) brain BrMs. Here we show that MI BrMs exhibit robust immune infiltration, whereas HI lesions are immunosuppressed. However, histological differentiation between MI and HI can be challenging because of subjective margin assessment. Here, using highly multiplexed spatial proteomics on 119 tumor sections from 46 patients with BrMs, we identify CHI3L1 as a key mediator of the immunosuppressive microenvironment in HI BrMs. In preclinical models, genetic deletion of CHI3L1 converts immune-cold metastases into lymphocyte-rich, ICI-responsive lesions infiltrated by granzyme B + CD8 + T cells. In BrM patients treated with ICI, immunohistochemical quantification of CHI3L1 expression was a stronger predictor of ICI response than traditional MI/HI classification. Thus, CHI3L1 represents a promising biomarker and therapeutic target for BrMs.
- Open Access
Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients
Alzheimer’s disease (AD) is the most common form of dementia globally; however, the aetiology of AD remains elusive hindering the development of effective therapeutics. MicroRNAs (miRNAs) are regulators of gene expression and have been of growing interest in recent studies in many pathologies including AD not only for their use as biomarkers but also for their implications in the therapeutic field. In this study, miRNA and protein profiles were obtained from brain tissues of different stage (Braak III-IV and Braak V-VI) of AD patients and compared to matched controls. The aim of the study was to identify in the late stage of AD, the key dysregulated pathways that may contribute to pathogenesis and then to evaluate whether any of these pathways could be detected in the early phase of AD, opening new opportunity for early treatment that could stop or delay the pathology. Six common pathways were found regulated by miRNAs and proteins in the late stage of AD, with one of them (Rap1 signalling) activated since the early phase. MiRNAs and proteins were also compared to explore an inverse trend of expression which could lead to the identification of new therapeutic targets. These results suggest that specific miRNA changes could represent molecular fingerprint of neurodegenerative processes and potential therapeutic targets for early intervention.
Open AccessCo-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients
Alzheimer’s disease (AD) is the most common form of dementia globally; however, the aetiology of AD remains elusive hindering the development of effective therapeutics. MicroRNAs (miRNAs) are regulators of gene expression and have been of growing interest in recent studies in many pathologies including AD not only for their use as biomarkers but also for their implications in the therapeutic field. In this study, miRNA and protein profiles were obtained from brain tissues of different stage (Braak III-IV and Braak V-VI) of AD patients and compared to matched controls. The aim of the study was to identify in the late stage of AD, the key dysregulated pathways that may contribute to pathogenesis and then to evaluate whether any of these pathways could be detected in the early phase of AD, opening new opportunity for early treatment that could stop or delay the pathology. Six common pathways were found regulated by miRNAs and proteins in the late stage of AD, with one of them (Rap1 signalling) activated since the early phase. MiRNAs and proteins were also compared to explore an inverse trend of expression which could lead to the identification of new therapeutic targets. These results suggest that specific miRNA changes could represent molecular fingerprint of neurodegenerative processes and potential therapeutic targets for early intervention.
- Open Access
- 27 October 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (20) , 5322-5335
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
Advances in transcriptomics have improved our understanding of leukemic development and helped to enhance the stratification of patients. The tendency of transcriptomic studies to combine AML samples, regardless of cytogenetic abnormalities, could lead to bias in differential gene expression analysis because of the differential representation of AML subgroups. Hence, we performed a horizontal meta-analysis that integrated transcriptomic data on AML from multiple studies, to enrich the less frequent cytogenetic subgroups and to uncover common genes involved in the development of AML and response to therapy. A total of 28 Affymetrix microarray data sets containing 3940 AML samples were downloaded from the Gene Expression Omnibus database. After stringent quality control, transcriptomic data on 1534 samples from 11 data sets, covering 10 AML cytogenetically defined subgroups, were retained and merged with the data on 198 healthy bone marrow samples. Differentially expressed genes between each cytogenetic subgroup and normal samples were extracted, enabling the unbiased identification of 330 commonly deregulated genes (CODEGs), which showed enriched profiles of myeloid differentiation, leukemic stem cell status, and relapse. Most of these genes were downregulated, in accordance with DNA hypermethylation. CODEGs were then used to create a prognostic score based on the weighted sum of expression of 22 core genes (CODEG22). The score was validated with microarray data of 5 independent cohorts and by quantitative real time-polymerase chain reaction in a cohort of 142 samples. CODEG22-based stratification of patients, globally and into subpopulations of cytologically healthy and elderly individuals, may complement the European LeukemiaNet classification, for a more accurate prediction of AML outcomes.
- 27 October 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (20) , 5322-5335
Open AccessHorizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
Advances in transcriptomics have improved our understanding of leukemic development and helped to enhance the stratification of patients. The tendency of transcriptomic studies to combine AML samples, regardless of cytogenetic abnormalities, could lead to bias in differential gene expression analysis because of the differential representation of AML subgroups. Hence, we performed a horizontal meta-analysis that integrated transcriptomic data on AML from multiple studies, to enrich the less frequent cytogenetic subgroups and to uncover common genes involved in the development of AML and response to therapy. A total of 28 Affymetrix microarray data sets containing 3940 AML samples were downloaded from the Gene Expression Omnibus database. After stringent quality control, transcriptomic data on 1534 samples from 11 data sets, covering 10 AML cytogenetically defined subgroups, were retained and merged with the data on 198 healthy bone marrow samples. Differentially expressed genes between each cytogenetic subgroup and normal samples were extracted, enabling the unbiased identification of 330 commonly deregulated genes (CODEGs), which showed enriched profiles of myeloid differentiation, leukemic stem cell status, and relapse. Most of these genes were downregulated, in accordance with DNA hypermethylation. CODEGs were then used to create a prognostic score based on the weighted sum of expression of 22 core genes (CODEG22). The score was validated with microarray data of 5 independent cohorts and by quantitative real time-polymerase chain reaction in a cohort of 142 samples. CODEG22-based stratification of patients, globally and into subpopulations of cytologically healthy and elderly individuals, may complement the European LeukemiaNet classification, for a more accurate prediction of AML outcomes.
- Top Cited PapersOpen Access
- 29 March 2019
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 6 (2) , 14
An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology
In its classical view, the renin angiotensin system (RAS) was defined as an endocrine system involved in blood pressure regulation and body electrolyte balance. However, the emerging concept of tissue RAS, along with the discovery of new RAS components, increased the physiological and clinical relevance of the system. Indeed, RAS has been shown to be expressed in various tissues where alterations in its expression were shown to be involved in multiple diseases including atherosclerosis, cardiac hypertrophy, type 2 diabetes (T2D) and renal fibrosis. In this chapter, we describe the new components of RAS, their tissue-specific expression, and their alterations under pathological conditions, which will help achieve more tissue- and condition-specific treatments.
- 29 March 2019
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 6 (2) , 14
Top Cited PapersOpen AccessAn Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology
In its classical view, the renin angiotensin system (RAS) was defined as an endocrine system involved in blood pressure regulation and body electrolyte balance. However, the emerging concept of tissue RAS, along with the discovery of new RAS components, increased the physiological and clinical relevance of the system. Indeed, RAS has been shown to be expressed in various tissues where alterations in its expression were shown to be involved in multiple diseases including atherosclerosis, cardiac hypertrophy, type 2 diabetes (T2D) and renal fibrosis. In this chapter, we describe the new components of RAS, their tissue-specific expression, and their alterations under pathological conditions, which will help achieve more tissue- and condition-specific treatments.
- 30 November 2018
- Published by Elsevier
Contributors
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, 334-342
Cellular distribution and interaction between extended renin-angiotensin-aldosterone system pathways in atheroma
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, 334-342
Cellular distribution and interaction between extended renin-angiotensin-aldosterone system pathways in atheroma
- 6 July 2017
- Published by Springer Nature in Hypertension Research
- Vol. 40 (11) , 903-909
Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
RAAS, a major pharmacological target in cardiovascular medicine, is inhibited by pharmacological classes including angiotensin converting enzyme (ACE) inhibitors (ACEIs), angiotensin-II type 1 blockers (ARBs) and aldosterone receptors antagonists, in addition to the recently introduced direct renin inhibitors (DRIs). However, currently used RAAS inhibitors still cannot achieve their desired effects and are associated with certain drawbacks, such as adverse side effects, incomplete blockage of the system and poor end-organ protection. In this review, we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.
- 6 July 2017
- Published by Springer Nature in Hypertension Research
- Vol. 40 (11) , 903-909
Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
RAAS, a major pharmacological target in cardiovascular medicine, is inhibited by pharmacological classes including angiotensin converting enzyme (ACE) inhibitors (ACEIs), angiotensin-II type 1 blockers (ARBs) and aldosterone receptors antagonists, in addition to the recently introduced direct renin inhibitors (DRIs). However, currently used RAAS inhibitors still cannot achieve their desired effects and are associated with certain drawbacks, such as adverse side effects, incomplete blockage of the system and poor end-organ protection. In this review, we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.
- Open Access
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 5135241
Acute Exposure to Cigarette Smoking Followed by Myocardial Infarction Aggravates Renal Damage in an In Vivo Mouse Model
Cigarette smoking (S) is a risk factor for progressive chronic kidney disease, renal dysfunction, and renal failure. In this study, the effect of smoking on kidney function was investigated in a mouse model of myocardial infarction (MI) using 4 groups: control (C), smoking (S), MI, and S+MI. Histological analysis of S+MI group showed alterations in kidney structure including swelling of the proximal convoluted tubules (PCTs), thinning of the epithelial lining, focal loss of the brush border of PCTs, and patchy glomerular retraction. Molecular analysis revealed that nephrin expression was significantly reduced in the S+MI group, whereas sodium‐hydrogen exchanger‐1 (NHE‐1) was significantly increased, suggesting altered glomerular filtration and kidney functions. Moreover, S+MI group, but not S alone, showed a significant increase in the expression of connective tissue growth factor (CTGF) and fibrotic proteins fibronectin (FN) and α‐smooth muscle actin (SMA), in comparison to controls, in addition to a significant increase in mRNA levels of IL‐6 and TNF‐α inflammatory markers. Finally, reactive oxygen species (ROS) production was significantly accentuated in S+MI group concomitant with a significant increase in NOX‐4 protein levels. In conclusion, smoking aggravates murine acute renal damage caused by MI at the structural and molecular levels by exacerbating renal dysfunction.
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 5135241
Open AccessAcute Exposure to Cigarette Smoking Followed by Myocardial Infarction Aggravates Renal Damage in an In Vivo Mouse Model
Cigarette smoking (S) is a risk factor for progressive chronic kidney disease, renal dysfunction, and renal failure. In this study, the effect of smoking on kidney function was investigated in a mouse model of myocardial infarction (MI) using 4 groups: control (C), smoking (S), MI, and S+MI. Histological analysis of S+MI group showed alterations in kidney structure including swelling of the proximal convoluted tubules (PCTs), thinning of the epithelial lining, focal loss of the brush border of PCTs, and patchy glomerular retraction. Molecular analysis revealed that nephrin expression was significantly reduced in the S+MI group, whereas sodium‐hydrogen exchanger‐1 (NHE‐1) was significantly increased, suggesting altered glomerular filtration and kidney functions. Moreover, S+MI group, but not S alone, showed a significant increase in the expression of connective tissue growth factor (CTGF) and fibrotic proteins fibronectin (FN) and α‐smooth muscle actin (SMA), in comparison to controls, in addition to a significant increase in mRNA levels of IL‐6 and TNF‐α inflammatory markers. Finally, reactive oxygen species (ROS) production was significantly accentuated in S+MI group concomitant with a significant increase in NOX‐4 protein levels. In conclusion, smoking aggravates murine acute renal damage caused by MI at the structural and molecular levels by exacerbating renal dysfunction.
- 1 December 2016
- Published by Wolters Kluwer Health in Hypertension
- Vol. 68 (6) , 1375-1384
Transcriptomic Analysis Reveals Novel Transcription Factors Associated With Renin–Angiotensin–Aldosterone System in Human Atheroma
Despite the well-known role of the renin–angiotensin–aldosterone system (RAAS) in atheroma, its global local organization is poorly understood. In this study, we used transcriptomic meta-analysis to reveal the local transcriptional organization and regulation of 37 extended RAAS (extRAAS) genes in atheroma. Expression analysis and hierarchical clustering were done on extRAAS genes in 32 paired early and advanced atherosclerotic lesions. Contrary to receptor-coding transcripts, multiple angiotensin-metabolizing enzymes showed higher expression in advance, in comparison to early lesions. Interestingly, similar results were obtained from GEO data sets containing human (n=839) and mouse (n=18) atherosclerotic samples, but different from normal human (n=11) arterial tissues. The expression and coordination patterns were then used to construct transcriptional maps of extRAAS, displaying favored pathways in atheroma. Three coexpression modules (M1, M2, and M3) with >80% reproducibility across human atheroma data sets were identified. M1 and M3 contained angiotensin-metabolizing enzymes transcripts, whereas M2 contained proatherogenic receptor-coding transcripts. Interestingly, M1 and M2 were negatively correlated. A total of 21 transcription factors with enriched binding sites in the promoters of coordinated genes were extracted, among which IRF5, MAX, and ETV5 showed significant positive correlations with M1, but negative correlations with M2. However, ETS1 and SMAD1 transcripts were positively correlated to receptor-coding genes in M2. Despite sharing some similarities in extRAAS organization with kidney and adipose, atheroma showed specific correlations between extRAAS and transcription factors. In conclusion, our transcriptional map helps in designing more efficient treatments for atherosclerosis. In addition, the identified transcription factors provide a basis for the discovery of atheroma-specific modulators of extRAAS.
- 1 December 2016
- Published by Wolters Kluwer Health in Hypertension
- Vol. 68 (6) , 1375-1384
Transcriptomic Analysis Reveals Novel Transcription Factors Associated With Renin–Angiotensin–Aldosterone System in Human Atheroma
Despite the well-known role of the renin–angiotensin–aldosterone system (RAAS) in atheroma, its global local organization is poorly understood. In this study, we used transcriptomic meta-analysis to reveal the local transcriptional organization and regulation of 37 extended RAAS (extRAAS) genes in atheroma. Expression analysis and hierarchical clustering were done on extRAAS genes in 32 paired early and advanced atherosclerotic lesions. Contrary to receptor-coding transcripts, multiple angiotensin-metabolizing enzymes showed higher expression in advance, in comparison to early lesions. Interestingly, similar results were obtained from GEO data sets containing human (n=839) and mouse (n=18) atherosclerotic samples, but different from normal human (n=11) arterial tissues. The expression and coordination patterns were then used to construct transcriptional maps of extRAAS, displaying favored pathways in atheroma. Three coexpression modules (M1, M2, and M3) with >80% reproducibility across human atheroma data sets were identified. M1 and M3 contained angiotensin-metabolizing enzymes transcripts, whereas M2 contained proatherogenic receptor-coding transcripts. Interestingly, M1 and M2 were negatively correlated. A total of 21 transcription factors with enriched binding sites in the promoters of coordinated genes were extracted, among which IRF5, MAX, and ETV5 showed significant positive correlations with M1, but negative correlations with M2. However, ETS1 and SMAD1 transcripts were positively correlated to receptor-coding genes in M2. Despite sharing some similarities in extRAAS organization with kidney and adipose, atheroma showed specific correlations between extRAAS and transcription factors. In conclusion, our transcriptional map helps in designing more efficient treatments for atherosclerosis. In addition, the identified transcription factors provide a basis for the discovery of atheroma-specific modulators of extRAAS.